Table 5 summary of studies with chemoradiotherapy plus bevacizumab
Study | Phase | N. of patients | Staging | Radiotherapy Gy/fractions/weeks | Bevacizumab | Concomitant chemotherapy | pCR N.% | Downstaging N.% | R0% |
|---|---|---|---|---|---|---|---|---|---|
Czito et al. [14] | I | 11 | II-IV | 50.4/28/5.5 | 15 mg/Kg 1st dose | Capecitabine: 500–825 mg/m2/bid 5 days/week | 2/11 18.2% | Overall: 81.8% | 81.8% |
10 mg/Kg days 8, 22 | Oxaliplatin 50–75 mg/m2/1, 8, 15, 22, 29 | ||||||||
Willett et a [10] | II | 32 | T3-T4 | 50.4/28/5.5 | 5-10 mg/Kg days 1, 8, 15, 22 | Fluorouracile: 225 mg/m2/24 hours/4 cycles | 5/32 16% | T stage: 50% N stage: 56.5% | 93.7% |
Crane et al. [16] | II | 25 | T3N0/T3N1 | 50.4/28/5.5 | 5 mg/Kg 3 doses | Capecitabine: 900 mg/m2/bid 5 days/week | 8/25 32% | T stage: 64% N stage: 15% | 100% |
Nogué et al. [18] | II | 47 | T3N0-T4N2 | 50.4/25/5.5 | 7 mg/Kg induction 4 cycles | Capecitabine: 825 mg/m2/bid 5 days/week | 16/45 36% | - | 97.9% |
5 mg/Kg days 1, 15, 29 | |||||||||
Koukourakis et al. [17] | II | 19 | T3 and/or N+ | Hypofractionated accelerated | 5 mg/Kg 2 doses | Capecitabine: 600 mg/m2/bid 5 days/week | 7/19 36.8% | - | - |
[19] | II | 61 | T2N1-T4N2 | 50.4/28/5.5 | 5 mg/Kg days −14, 1, 15, 29 | Capecitabine: 825 mg/m2/bid 5 days/week | 8/60 13.3% | T stage: 64% N stage: 15% Overall: 73.8% | 95% |
Dipetrillo et al. [20] | II | 26 | T2N0-T4Nx | 50.4/25/5.5 | 5 mg/Kg days induction and then days 1, 15, 29 | Fluorouracile: 200 mg/m2/24 hours | 5/25 20% | - | - |
Oxaliplatin 50 mg/m2/1, 8, 15, 22, 29, 36 | |||||||||
Landry et al. [24] | II | 57 | T3-T4 | 50.4/28/5.5 | 5 mg/Kg days 1, 15, 29 | Capecitabine: 825 mg/m2/bid 5 days/week | 9/57 17% | Overall: 59% | - |
Oxaliplatin 50 mg/m2/1, 8, 15, 22, 29 | |||||||||
Gasparini et al. [21] | II | 43 | T2N1-T4N2 | 50.4/28/5.5 | 5 mg/Kg days −14, 1, 15, 29 | Capecitabine: 825 mg/m2/bid 5 days/week | 6/43 14% | T Stage: 34.9% N stage: 41.86% | - |
Spigel et al. [23] | II | 35 (cohort A) | II/III | 50.4/28/5.5 | 5 mg/Kg days 1, 15 | Fluorouracile: 225 mg/m2/24 hours days 1 to 42 | 10/35 29% | - | - |
Resch et al. [22] | II | 8 | cT3 | 45/-/5 | 5 mg/Kg days 1, 15, 29 | Capecitabine: 825 mg/m2/bid 5 days/week 4 weeks | 2/8 25% | Overall: 37.5% | - |
Kennecke et al. [15] | II | 42 | T2-T4 N2 | 50.4/28/5.5 | 5 mg/Kg days −14, 1, 15, 29 | Capecitabine: 825 mg/m2/bid days 1–14, 22-35 | 7/42 18.4% | - | 92% |
Oxaliplatin 50 mg/m2/1, 8, 22, 29 |